Back to today’s briefing

Story perspectives

CSL Slashes Profit Outlook, Shares Plunge 16.6%

10/28/2025

46 10

Summary

Story summary

Australian CSL cut its profit outlook and delayed vaccine division spin-off after a drop in U.S. flu immunisation rates.
CSL's shares fell up to 16.6% to A$176.23, near a seven-year low.
It lowered revenue growth to 2%–3% and net profit growth to 4%–7%, from 4%–5% and 7%–10%.
At the annual meeting, shareholders voted 42% against executive pay, and the demerger will proceed when market conditions allow for maximizing shareholder value.

1 of 1

Story summary

Australian CSL cut its profit outlook and delayed vaccine division spin-off after a drop in U.S. flu immunisation rates.
CSL's shares fell up to 16.6% to A$176.23, near a seven-year low.
It lowered revenue growth to 2%–3% and net profit growth to 4%–7%, from 4%–5% and 7%–10%.
At the annual meeting, shareholders voted 42% against executive pay, and the demerger will proceed when market conditions allow for maximizing shareholder value.